BiomX -Model BX005 -Atopic Dermatitis
We are developing BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. This program leverages know-how and capabilities acquired under our previous programs with regard to topical formulation and clinical testing. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. aureus isolated from the skin of subjects from U.S. and Europe, including antibiotic resistant strains.
Companies active in the dermatology space are aware of the enormous patient potential in the AD market. The approval of Dupixent has transformed the treatment of AD and has addressed the unmet need of treating severe refractory patients. Nevertheless, systemic treatments have multiple side effects and there remains an enormous opportunity in the topical treatment arena for patients who are not candidates for systemic therapies, including patients suffering from mild to moderate disease and pediatric patients whose parents are particularly wary of the safety aspects of treatment and are seeking safe and natural alternatives.
The relationship between AD and skin bacteria has led to different anti-microbial treatment approaches including the use of bleach baths. On the background of predisposing factors, Staphylococcus aureus (S. aureus) is thought to contribute to development and exacerbation of inflammation in AD skin through release of various virulence factors that affect both keratinocytes and immune cells. S. aureus is more abundant on the skin of AD patients than non-AD individuals and in lesional skin than non-lesional skin. It also increases in abundance, becoming the dominant bacteria, when patients experience flares. By reducing the load of S. aureus, our phage therapy is intended to shift the skin microbiome composition to its ‘pre-flare’ state and provide a clinical benefit.